Lv1
90 积分 2024-04-19 加入
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial
6天前
已完结
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
6天前
已完结
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
6天前
已完结
Analysis of the Complement System in the Clinical Immunology Laboratory
2个月前
已完结
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier
3个月前
已完结
Antibody-oligonucleotide conjugates in cancer therapy: Potential and Promise
3个月前
已关闭
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
3个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
4个月前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
4个月前
已完结
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
4个月前
已完结
皖公网安备34019202002308
